Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews
Lifespan
25 participants
Jul 1, 2023
OBSERVATIONAL
Summary
This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders.
Eligibility
Inclusion Criteria4
- English speaking
- Over the age of 18
- Diagnosed with opioid use disorder
- \- Employed or contracted by Rhode Island Department of Corrections (for organizational staff interviews) and involved with the Medication for Addiction Treatment (MAT) program
Exclusion Criteria1
- \- If not permitted by their organizational union to participate
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06354465